Biotech Startups
9,830 companies tagged Biotech, with their investors and founders.
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk. The company uses a platform approach to tune drug candidates across a spectrum from inhibitors to full agonists.
3 investors
Epirium Bio develops novel oral therapeutics targeting mitochondrial dysfunction and muscle diseases, particularly muscular dystrophy. The company's lead compound, EPM-01, is in Phase 1 clinical development for Becker muscular dystrophy.
3 investors
Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform. The company serves patients with difficult-to-treat cancers across oncology.
3 investors
Equator Therapeutics develops first-in-class drugs targeting mitochondrial thermogenesis to treat obesity and metabolic disorders by restoring the body's natural heat production mechanism. The company uses bioelectricity research and high-throughput assays to identify selective activators of thermogenic compounds in mitochondria.
3 investors
Espervita Therapeutics develops metabolic reprogramming therapies targeting liver and kidney disease, with a lead program in acetyl-CoA metabolic enzyme inhibitors. The company focuses on treating progressive metabolic liver diseases and related conditions.
3 investors
3 investors
Everbloom develops lab-grown noble fibers from protein waste as sustainable alternatives to animal and synthetic materials for luxury fashion. The company produces fibers with lower environmental impact than wool, cashmere, and silk across land use, water consumption, and emissions.
3 investors
EVOQ Therapeutics develops immunotherapies targeting autoimmune diseases by using proprietary NanoDisc technology to restore immune tolerance. The company focuses on treating conditions like Type 1 Diabetes, Multiple Sclerosis, and Lupus through novel therapeutic approaches.
3 investors
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases. The therapies target the central nervous system to address the root cause of neurodegeneration.
3 investors
Excelsior Sciences develops automated chemistry technology for small-molecule discovery and manufacturing, targeting pharmaceutical and materials development. Its proprietary Blocc Chemistry platform uses AI-guided synthesis to accelerate drug discovery through machine-readable chemical building blocks and closed-loop learning.
3 investors
ExeVir is a biotech company developing vaccines and antibody-based therapeutic strategies targeting respiratory viruses including influenza and respiratory syncytial virus. The company serves patients affected by infectious diseases through novel vaccine approaches and immunological interventions.
3 investors
ExpressionEdits builds a computational platform, the Genetic Syntax Engine, that uses AI and intron-based transgene design to improve protein expression for therapeutic applications. The company develops an internal pipeline of therapeutic proteins and works on gene therapy partnerships.
3 investors
Eywa is a team of scientists and innovators focused on advancing mental health through research and partnerships.
3 investors
Fabric Genomics provides an AI-based platform for next-generation sequencing (NGS) analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The platform serves hospitals, clinical laboratories, and academic medical centers.
3 investors
Felix Biotechnology develops a digital platform for designing viruses intended to combat antimicrobial resistance.
3 investors
Kyntra Bio (formerly FibroGen) is a clinical-stage biopharmaceutical company developing therapies for oncology and rare diseases, including serious and life-threatening conditions. Its pipeline includes drug candidates such as roxadustat and FG-3246.
3 investors
Filtricine is a clinical-stage biotechnology company developing nutrition-based medical food products for disease control, using its Targeted Nutrients Deprivation (TND) approach to starve cancer cells while providing balanced nutrition to patients. Its focus is on "food as medicine" interventions for cancer and other common diseases.
3 investors
1STBIO (νΌμ€νΈλ°μ΄μ€) is a biotechnology company developing drug programs, including the HPK1 inhibitor immuno-oncology candidate FB849 and the NLY02 program. It focuses on advancing therapeutic pipelines to bring treatments to patients.
3 investors
First Light Diagnostics develops the MultiPath benchtop analyzer, an instrument for rapid diagnostic testing. The company operates in the in-vitro diagnostics space.
3 investors
Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells. The company has lead programs in prostate cancer and advanced urothelial cancer, and maintains a partnership with Roche.
3 investors
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives. The company focuses on vessel health and blood flow optimization for applications ranging from athletic performance to sexual wellness.
3 investors
Flightpath Biosciences develops microbiome-sparing, pathogen-specific drug candidates to treat infection-associated diseases by selectively targeting harmful bacteria while preserving healthy microbial communities. The company focuses on small molecule therapeutics for chronic and complex diseases, particularly those linked to pathogenic bacteria such as Crohn's disease.
3 investors
3 investors
Forge Biologics is a US-based gene therapy CDMO (contract development and manufacturing organization) offering AAV manufacturing services, technologies, and infrastructure. It supports gene therapy developers across early development, clinical trials, and commercial production, and is a subsidiary of the Ajinomoto Group.
3 investors